Research programme: oncolytic viruses - Transgene

Drug Profile

Research programme: oncolytic viruses - Transgene

Alternative Names: anti-PD-1 immune checkpoint inhibitor - Transgene; J43-armed-Western Reserve oncolytic vaccinia virus

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Transgene
  • Class Antibodies; Antineoplastics; Gene-directed enzyme-prodrug therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Checkpoint kinase inhibitors; Immunomodulators; PDCD 1 protein inhibitors; Prodrug activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 30 Mar 2017 Interim data from preclinical study in Solid tumours released by Transgene
  • 20 Mar 2017 Transgene files for patent protection for an oncolytic Vaccinia Virus expressing an anti-PD1 antibody in
  • 05 Sep 2016 Preclinical development is ongoing France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top